Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Acquisitions & Divestments: 2015-2024

Historic Change in Acquisitions & Divestments for Assembly Biosciences (ASMB) over the last 10 years, with Dec 2024 value amounting to $130.7 million.

  • Assembly Biosciences' Change in Acquisitions & Divestments fell 42.09% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.8 million, marking a year-over-year increase of 2.28%. This contributed to the annual value of $130.7 million for FY2024, which is 101.03% up from last year.
  • Per Assembly Biosciences' latest filing, its Change in Acquisitions & Divestments stood at $130.7 million for FY2024, which was up 101.03% from $65.0 million recorded in FY2023.
  • Assembly Biosciences' Change in Acquisitions & Divestments' 5-year high stood at $221.6 million during FY2020, with a 5-year trough of $65.0 million in FY2023.
  • For the 3-year period, Assembly Biosciences' Change in Acquisitions & Divestments averaged around $94.6 million, with its median value being $88.0 million (2022).
  • In the last 5 years, Assembly Biosciences' Change in Acquisitions & Divestments tumbled by 49.77% in 2022 and then surged by 101.03% in 2024.
  • Assembly Biosciences' Change in Acquisitions & Divestments (Yearly) stood at $221.6 million in 2020, then decreased by 20.94% to $175.2 million in 2021, then crashed by 49.77% to $88.0 million in 2022, then declined by 26.12% to $65.0 million in 2023, then skyrocketed by 101.03% to $130.7 million in 2024.